Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Oedema peripheral? 56 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 56 reports of Oedema peripheral have been filed in association with BASILIXIMAB (Simulect). This represents 0.8% of all adverse event reports for BASILIXIMAB.

56
Reports of Oedema peripheral with BASILIXIMAB
0.8%
of all BASILIXIMAB reports
1
Deaths
44
Hospitalizations

How Dangerous Is Oedema peripheral From BASILIXIMAB?

Of the 56 reports, 1 (1.8%) resulted in death, 44 (78.6%) required hospitalization, and 10 (17.9%) were considered life-threatening.

Is Oedema peripheral Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 56 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Oedema peripheral?

AMBRISENTAN (2,959) TREPROSTINIL (2,816) ADALIMUMAB (2,356) LENALIDOMIDE (2,298) AMLODIPINE (2,076) PREDNISONE (2,029) METHOTREXATE (1,939) MACITENTAN (1,932) RITUXIMAB (1,698) TOCILIZUMAB (1,574)

Which BASILIXIMAB Alternatives Have Lower Oedema peripheral Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Oedema peripheral Reports All Drugs Causing Oedema peripheral BASILIXIMAB Demographics